Posting fresh info about MS, for people with MS and their supporters

Merck Refiles Cladribine for US Approval

FRANKFURT (Dow Jones)–German pharmaceutical and chemicals company Merck KGaA (MRK.XE) said Tuesday it resubmitted its application for U.S. regulatory approval of oral multiple sclerosis treatment cladribine–seven months after the Food and Drug Administration rejected its initial submission.

SPEAK / ADD YOUR COMMENT
Comments are moderated.

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Return to Top
Feeds

Search


SUPPORT / Find out More


 

TAG / CLOUD

aan, alemtuzumab, avonex, betaseron, biogen, bioms medical corp, campath, ccsvi, cis, cladribine, clarity, cognitive dysfunction, copaxone, daclizumab, dirucotide, discovery, ectrims, elan, fampridine-sr, fatigue, fda, fda fast track status, fingolimod, fty-720, genzyme, gilenia, gilenya, interferons, laquinimod, merck, merck/serono, novartis, oral ms therapies, phase iii, pml, rebif, rrms, serono, smoking, spms, stem cells, teriflunomide, teva, therapy, tysabri

ARCHIVES / PAST ARTICLES



Follow me on Twitter
Friend me on Facebook
Subscribe by Email




Bookmark and Share


Wordpress Engine. Upstart Theme. Better Project.